{"id":"NCT02985749","sponsor":"Massachusetts General Hospital","briefTitle":"A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder","officialTitle":"A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-09","primaryCompletion":"2019-01-09","completion":"2019-01-09","firstPosted":"2016-12-07","resultsPosted":"2023-08-16","lastUpdate":"2024-07-01"},"enrollment":7,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Autism Spectrum Disorder","Pervasive Developmental Disorder","ASD","PDD"],"interventions":[{"type":"DRUG","name":"Intranasal Oxytocin","otherNames":["Syntocinon"]}],"arms":[{"label":"Oxytocin- Participants ages 12-17","type":"EXPERIMENTAL"},{"label":"Oxytocin- Participants ages 18-55","type":"EXPERIMENTAL"}],"summary":"This study is an 8-week pilot trial with oxytocin nasal spray (Syntocinon) as a treatment for social impairment in children and adults with high functioning autism spectrum disorders (ASD). The investigators hypothesize that oxytocin will be safe, tolerable, and effective in improving social deficits in individuals with ASD.","primaryOutcome":{"measure":"Change in ASD Symptoms Social Responsiveness Scale 2 (SRS-2) Scale From Baseline to Week 8","timeFrame":"8 weeks","effectByArm":[{"arm":"Oxytocin- Participants Ages 12-17","deltaMin":-39.5,"sd":12},{"arm":"Oxytocin- Participants Ages 18-55","deltaMin":-29,"sd":9.8}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":12},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Ear infection","Foot pain","Faint/dizzy after blood drawn","Drowsiness","Allergy"]}}